Abstract: The present invention relates to a method for the diagnosis of prostate carcinoma comprising the determination of annexin A3 (ANXA3) and/or autoantibodies against ANXA3 with a specific reagent. The method allows differentiation between benign, premalignant and malignant conditions. Further, the method has a prognostic relevance.

Abstract: The invention relates to the use of at least one isoform of progesterone receptor membrane component 1 (PGRMC1) as diagnostic marker and/or therapeutic target for diseases associated with neogenin and/or DCC and/or for the manufacture of a medicament for treatment of diseases associated with neogenin and/or DCC, the use of at least one reagent that influences the function of at least one isoform of PGRMC1 for the manufacture of a medicament for treatment of diseases associated with neogenin and/or DCC, the use of at least one isoform of PGRMC1 for influencing abundance or subcellular localisation of at least one class of molecules interacting with PGRMC1, an assay kit for diagnosis and/or therapy of diseases associated with neogenin and/or DCC, comprising at least one isoform of PGRMC1 and/or at least one reagent that influences the function of at least one isoform of PGRMC1, the use of at least one isoform of PGRMC1 as diagnostic marker in diagnosis for diseases associated with aberrant bio-logical phenotype

Abstract: The invention relates, inter alia, to the use of neuregulin-? as a target in a screening method for active compounds, in particular for exerting an influence on changes in calcium concentration which are mediated by glutamate receptors. The invention furthermore relates to the use of neuregulins, preferably a neuregulin isoform having an isoelectric point in the range from pH 4.3 to 5.0, as a target for detecting and/or exerting an influence on neuronal processes, in particular for exerting an influence on long-term memory. Neuregulins, in particular neuregulin-? and also substances which exert an influence on the status, i.e. the expression and/or post-translational modification, of neuregulin-?, can therefore be used as agents for controlling the course of, treating and/or alleviating neuronal diseases, e.g. Alzheimer's disease.

Abstract: The present invention relates to new pharmaceutical uses of 4-azasteroid compounds, in particular of Finasteride/Dutasteride/Dutasteride and Dutasteride, particularly preferred of Finasteride/Dutasteride/Dutasteride, and its pharmaceutically acceptable derivatives, and combinations comprising said compounds. The invention also features generally the use of a modulator compound of neuroprotective conditions via beta subunits of shaker-type voltage-gated potassium channels and/or via members of solute carriers family 25, in particular Aralar (member 12) and adenine-nucleotide translocators 1 & 2 (member 4 & 5) and/or via a 4-nitrophenylphosphatase domain and non-neuronal SNAP25-like protein homolog 1 (NIPSNAP 1) as a neuroprotective medicament, particularly as a medicament for the prevention and/or treatment of neurological diseases such as dementia, Parkinson, Alzheimer, schizophrenia or epilepsy.

Abstract: The invention relates, inter alia, to the use of neuregulin-? as a target in a screening method for active compounds, in particular for exerting an influence on changes in calcium concentration which are mediated by glutamate receptors. The invention furthermore relates to the use of neuregulins, preferably a neuregulin isoform having an isoelectric point in the range from pH 4.3 to 5.0, as a target for detecting and/or exerting an influence on neuronal processes, in particular for exerting an influence on long-term memory. Neuregulins, in particular neuregulin-? and also substances which exert an influence on the status, i.e. the expression and/or post-translational modification, of neuregulin-?, can therefore be used as agents for controlling the course of, treating and/or alleviating neuronal diseases, e.g. Alzheimer's disease.

Abstract: A method treats urogenital and/or intestinal tract cancer and includes administering a therapeutically effective amount of at least one annexion protein, annexin of A3, to a mammal.

Abstract: The invention relates to a method for the enrichment, isolation and/or identification of cleavage products of at least one enzyme from a sample. According to the invention, an enzymatically inactive mutant of a protease is used as an affinity material, said mutant furthermore maintaining its specific substrate nature. At least one cleavage product of the protease of which the mutant is used, and at least one cleavage product of the enzyme of which the cleavage products are to be analyzed, comprise at least one structural similarity.

Abstract: The present invention relates to generally to the cytoprotective activity of mixed muscarinic inhibition/PARP modulation and in particular to the use of dual inhibitors of M1 muscarinic receptor and poly(ADP-ribose) polymerase (PARP) as neuroprotective medicaments, particularly as medicaments for the prevention and/or treatment of neurological diseases. Particularly preferred compounds are condensed diazepinones, e.g. condensed benzodiazepinones such as pirenzepine or compounds which are metabolized to condensed benzodiazepinones such as olanzapine.

Abstract: x The present invention relates generally to the cytoprotective activity of mixed muscarinic inhibition/PARP modulation and in particular to the use of dual inhibitors of M1 muscarinic receptor and poly(ADP-ribose) polymerase (PARP) as epithelioprotective medicaments, particularly as medicaments for the prevention and/or treatment of at least one of the common lung diseases associated with a significant inflammatory component such as severe sepsis, acute lung injury, acute respiratory distress syndrome, cystic fibrosis, asthma, allergic rhinitis, chronic obstructive pulmonary disease, pulmonary fibrosis, systemic sclerosis, pneumoconiosis or lung cancer. Particularly preferred compounds are condensed diazepinones, e.g. condensed benzodiazepinones such as pirenzepine or compounds which are metabolized to condensed benzodiazepinones such as olanzapine.

Abstract: The invention relates to the use of various proteins as diagnostic markers for cancerous diseases. In particular, the use of the annexin A3 protein is preferred. Preferably an increased regulation of annexin A3 is analysed in comparison to controls. The invention also relates to the use of active substances for producing a medicament used in the treatment of cancer, said substances influencing the activity and/or abundance of various characteristic proteins.